Abstract

Background: Several major randomized control studies have demonstrated that mepolizumab, an anti-IL-5 monoclonal antibody, is effective for patients with severe eosinophilic asthma who show exacerbation or require systemic corticosteroid maintenance therapy. However, the predictive factors of the response to mepolizumab other than blood eosinophil count are unclear in clinical practice.

Objective: To elucidate the predictive factors of the response to mepolizumab for patients with severe eosinophilic asthma.

 

CC0 Creative Commons, Pixabay

Read more…

 

The post Efficacy of Mepolizumab for Patients With Severe Asthma and Eosinophilic Chronic Rhinosinusitis appeared first on Healthier Environment Living Program.